Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
September 12 2018 - 6:30PM
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX)
today held its Annual and Special Meeting of Shareholders (the
“Meeting”) in Calgary, Alberta. A total of 126,864,830 shares
(approximately 71.50% of outstanding common shares) were
represented in person or by proxy.
During business proceedings at the Meeting,
shareholders elected six (6) Board members until the next annual
meeting. The voting results of shares represented at the Meeting
for individual directors were as follows:
|
|
|
|
|
|
Votes
For |
Votes Withheld |
Percent For |
Percent Withheld |
|
|
|
|
|
Donald J. McCaffrey |
119,460,894 |
341,143 |
99.72 |
0.28 |
Norma
Biln |
119,660,378 |
141,659 |
99.88 |
0.12 |
Shawn
Lu |
119,594,448 |
207,589 |
99.83 |
0.17 |
Kelly
McNeill |
119,661,978 |
140,059 |
99.88 |
0.12 |
Dr.
Eldon Smith |
119,681,648 |
120,389 |
99.90 |
0.10 |
Kenneth Zuerblis |
119,615,048 |
186,989 |
99.84 |
0.16 |
|
|
|
|
|
Resverlogix shareholders approved all
resolutions, including an amendment to the Corporation’s articles
to potentially consolidate the issued and outstanding common
shares, outlined in the Notice of Meeting and Management
Information Circular dated July 27, 2018 (the “Information
Circular”). The Information Circular is available on SEDAR at
www.sedar.com, and on the Resverlogix website at
www.resverlogix.com.
A webcast archive of the executive presentation
portion of the Meeting is available here.
The Corporation also announces that it expects
to file its unaudited interim Consolidated Financial Statements and
Management's Discussion & Analysis for the quarter ended July
31, 2018 with Canadian securities regulatory authorities on
September 14, 2018. These materials will be available on the
Resverlogix website, and on SEDAR, shortly after being filed.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease, diabetes mellitus,
chronic kidney disease, end-stage renal disease treated with
hemodialysis, neurodegenerative disease, Fabry disease, peripheral
artery disease and other orphan diseases, while maintaining a well
described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024